1
Kevin M Cottrell, Robert B Perni, Janos Pitlik: Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases. Vertex Pharmaceuticals Incorporated, Susan C Kelly, April 24, 2007: US07208600 (45 worldwide citation)

The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus an ...


2
Janos Pitlik, Kevin M Cottrell, Luc J Farmer, Robert B Perni, Lawrence F Courtney, John H van Drie, Mark A Murcko: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Susan C Kelly, Lisa A Dixon, September 25, 2007: US07273885 (42 worldwide citation)

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to ...


3
Luc J Farmer, Janos Pitlik, Robert B Perni, Lawrence F Courtney, John van Drie: Bridged bicyclic serine protease inhibitors. Vertex Pharmaceuticals Incorporated, Michael C Badia, Vertex Pharmaceuticals Incorporated, June 21, 2005: US06909000 (39 worldwide citation)

The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of ...


4
Luc J Farmer, Robert B Perni, Janos Pitlik, John H van Drie Jr: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals, Susan C Kelly, July 10, 2007: US07241796 (25 worldwide citation)

The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention furt ...


5
Shawn D Britt, Kevin M Cottrell, Robert B Perni, Janos Pitlik: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Michael C Badia, Vertex Pharmaceuticals Incorporated, September 19, 2006: US07109172 (24 worldwide citation)

The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus a ...


6
Robert B Perni, John J Court, Shawn D Britt, Janos Pitlik, John H van Drie: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Ropes & Gray, James F Haley Jr, Michele A Kercher, May 27, 2008: US07378422 (22 worldwide citation)

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to ...


7
Kevin M Cottrell, John Maxwell, Robert B Perni, Janos Pitlik: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Susan C Kelly, April 29, 2008: US07365092 (22 worldwide citation)

The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful ...


8
Jean Bemis, Jeremy S Disch, Pui Yee Ng, Christopher Oalmann, Robert B Perni, Chi B Vu: Sirtuin modulating compounds. Sirtris Pharmaceuticals, Ropes & Gray, February 22, 2011: US07893086 (18 worldwide citation)

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to agin ...


9
Robert Edward Babine, Shu Hui Chen, Ivan Collado, Cristina Garcia Paredes, John Irvin Glass, Deqi Guo, Ling Jin, Jason Eric Lamar, Raymond Samuel Parker III, Nancy June Snyder, Xicheng David Sun, Mark Joseph Tebbe, Frantz Victor, Q May Wang, Yvonne Yee Mai Yip, Robert B Perni, Luc Farmer: Peptidomimetic protease inhibitors. Vertex Pharmaceuticals Incorporated, Honigman Miller Schwartz and Cohn, Jonathan P O Brien, Kathryn D Soulier, October 26, 2010: US07820671 (17 worldwide citation)

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The in ...


10
Robert B Perni, John J Court, Shawn D Britt, Janos Pitlik, John H van Drie: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Ropes & Gray, James F Haley Jr, June 29, 2010: US07745444 (3 worldwide citation)

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to ...